Cargando…
Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
Both humoral and cellular anamnestic responses are significant for protective immunity against SARS-CoV-2. In the current study, the responses in elderly people before and after a fourth vaccine dose of BNT162b2 were compared to those of individuals immunized with three vaccine doses. Although a boo...
Autores principales: | Bar-Haim, Erez, Eliakim-Raz, Noa, Stemmer, Amos, Cohen, Hila, Elia, Uri, Ness, Asaf, Awwad, Muhammad, Ghantous, Nassem, Moskovits, Neta, Rotem, Shahar, Stemmer, Salomon M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101339/ https://www.ncbi.nlm.nih.gov/pubmed/35566774 http://dx.doi.org/10.3390/jcm11092649 |
Ejemplares similares
-
Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022) -
Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study
por: Eliakim-Raz, Noa, et al.
Publicado: (2022) -
Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
por: Eliakim-Raz, Noa, et al.
Publicado: (2021) -
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
por: Massarweh, Amir, et al.
Publicado: (2021) -
Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study
por: Massarweh, Amir, et al.
Publicado: (2022)